Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 1, 2026

NVIDIA Unveils Vera, the CPU for Agents

View original at finance.yahoo.com
NVIDIA Unveils Vera, the CPU for Agents NVIDIA 1.8x Faster Than x86 Processors to Drive Diverse Workloads Across Industries, Generating More Data Center Token Revenue NVIDIA Vera CPU RackNVIDIA Vera is a new class of processor enabling 1.8x faster task completion compared with x86 CPUs.·GlobeNewswire Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Vera drives more data center token revenue compared to x86 alternatives

    60% confidence

  • NVIDIA Grace CPUs have achieved nearly 2.5 million shipments to date

    60% confidence

  • NVIDIA Vera CPU is now in full production

    60% confidence

  • AI agents will be the largest users of computing; Vera is the first CPU designed for that future, built to run agentic AI at hyperscale with extraordinary performance, efficiency and programmability

    60% confidence

  • The NYSE processes more than 1.1 trillion messages per day and will scale capacity while optimizing latency using NVIDIA Vera CPUs in collaboration with Redpanda and HPE

    60% confidence

  • NYSE's focus is to optimize the latency, throughput and reliability of its unrivaled infrastructure

    60% confidence

  • NVIDIA Vera CPU achieves 1.8x faster task completion compared with x86 CPUs

    60% confidence

  • Vera serves as the CPU powering standalone Vera servers, NVIDIA Vera Rubin systems, and Vera BlueField-4 STX AI storage platforms

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
NVIDIA Unveils Vera, the CPU for Agents — Source | Via News | Finance Via News